Bempedoic acid (BA) is a novel first-in-class oral lipid-lowering therapy. BA has been approved by the European Medicinal Agency and Food and Drug Administration and has been commercialised throughout Europe since the end of 2020 as an add-on therapy in patients at high/very-high cardiovascular risk that are not at LDL-C goals with current lipid-lowering treatments. Recently, Italian lipid management experts gathered to discuss several open questions on BA characteristics and BArelated practical clinical issues. The panel permitted collection of its opinions in a ten Q&A format.
Aim: The aim of this viewpoint is to discuss and answer several open questions on BA characteristics and BA-related practical clinical issues.
Data synthesis: The data includes main phase III studies, subanalysis and meta-analysis on BA.
Conclusions: The panel permitted collection of its opinions in a ten Q&A format.
Keywords: ATP citrate lyase; Bempedoic acid; LDL-cholesterol; Lipid-lowering treatment; Novel LDL-C treatment.
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.